Nutriband Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 25.0K | $88.13K | 0.00% | Unchanged | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-04-29 | -1.89 | -0.04 | +97.88% |
| 2025-12-11 | -2.13 | -0.32 | +84.98% |
| 2025-09-09 | -0.17 | -2.12 | -1147.06% |
| 2025-05-30 | -0.16 | -0.12 | +25.00% |
| 2025-04-28 | -0.12 | -0.51 | -325.00% |
| 2023-04-26 | -0.05 | -0.17 | -242.60% |
| 2022-12-02 | -0.07 | -0.14 | -100.00% |
| 2022-09-08 | -0.07 | -0.12 | -75.00% |
| 2022-05-31 | -0.06 | -0.08 | -28.57% |
| 2022-04-29 | -0.09 | -0.19 | -111.81% |
| 2021-12-14 | -0.03 | -0.23 | -575.12% |
| 2021-09-03 | 0.01 | -0.07 | -923.34% |
| 2021-06-14 | — | -0.05 | — |
| 2021-04-02 | — | -0.33 | — |
| 2020-12-15 | -0.03 | -0.01 | +75.01% |
| 2020-09-11 | -0.06 | -0.03 | +42.85% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| NTRB | -9.59% | -15.70% | -23.13% | -46.31% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -12.55% | -11.06% | -19.68% | -59.00% |